Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2023
New Zealand Pharmaceutical Schedule - 1 November 2023
1 November 2023 - The November 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Oct 2023
End of temporary funding of palivizumab for preventing RSV
31 October 2023 - Palivizumab has been funded for the last two seasons from funding made available as part of the ...
Posted by Michael Wonder on 30 Sep 2023
New Zealand Pharmaceutical Schedule - 1 October 2023
1 October 2023 - The October 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 20 Sep 2023
Access to COVID-19 anti-viral treatments widened for more people at risk
20 September 2023 - PHARMAC is widening access to COVID-19 anti-virals to people who are vulnerable to severe infection from ...
Posted by Michael Wonder on 11 Sep 2023
Act’s productivity perspective on PHARMAC medication and treatments will hurt minorities
11 September 2023 - Act is proposing a “productivity perspective based on real lives” when it comes to delivering PHARMAC ...
Posted by Michael Wonder on 05 Sep 2023
Oncologists pen open letter to PHARMAC asking for more life-saving cancer drugs
5 September 2023 - Drug buying agency PHARMAC is not moving fast enough, says a gut cancer patient paying more ...
Posted by Michael Wonder on 04 Sep 2023
Working with Te Whatu Ora to enable better access to vaccines
4 September 2023 - This year, many New Zealanders received their vaccinations at pharmacies close to their homes or workplaces. ...
Posted by Michael Wonder on 04 Sep 2023
PHARMAC widens access to treatment for life-long bleeding disorder, severe haemophilia A
4 September 2023 - PHARMAC has confirmed it is widening access to emicizumab (Hemlibra) for the treatment of people with severe ...
Posted by Michael Wonder on 04 Sep 2023
ACT calls for "productivity focus" for PHARMAC
3 September 2023 - The policy was discussed on Q+A with Jack Tame by new candidate Todd Stephenson, who has ...
Posted by Michael Wonder on 04 Sep 2023
PHARMAC funds first treatment for primary progressive multiple sclerosis
4 September 2023 - PHARMAC has confirmed it is widening access to ocrelizumab (Ocrevus) as the first funded treatment for ...
Posted by Michael Wonder on 31 Aug 2023
New Zealand Pharmaceutical Schedule - 1 September 2023
1 September 2023 - The September 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 27 Aug 2023
PHARMAC announcement of more blood cancer medicines welcomed
27 August 2023 - Myeloma New Zealand is welcoming Pharmac's announcement of more blood cancer medicines, but says the country is ...
Posted by Michael Wonder on 24 Aug 2023
PHARMAC seeking bids from suppliers for multiple myeloma treatments
24 August 2023 - PHARMAC is seeking bids from suppliers for two medicines, lenalidomide and pomalidomide, for use in the ...
Posted by Michael Wonder on 23 Aug 2023
PHARMAC confirms transition to a trastuzumab biosimilar and widens access to other types of cancer
23 August 2023 - PHARMAC is transitioning to a trastuzumab biosimilar, Herzuma, from the currently funded brand, Herceptin, as a result ...
Posted by Michael Wonder on 22 Aug 2023
Suggestions Nat's cancer drug funding promise has put PHARMAC in a difficult position
22 August 2023 - It's being suggested National's cancer drug funding promise has put PHARMAC in a difficult position. ...